NEW YORK – Geller Biopharm, Inc successfully represented Klox Technologies Limited, a subsidiary of Klox Technologies Inc., in its transfer of selected patents and patent applications to Vetoquinol. Through this agreement, Vetoquinol now has full exclusive ownership of the rights to develop and commercialize Klox’s fluorescent light energy (FLE) products in animal health.
Matt Geller, Managing Director of Geller Biopharm, Inc., stated that “this is of significant value for both Klox and Vetoquinol. It provides Klox funding to pursue expansion of the use and markets for their product and provides Vetoquinol full rights to utilize Klox’s technology in the animal health field.”
About Klox Technologies
Klox Technologies Inc. is a regenerative medicine company focused on the development and commercialization of Fluorescent light energy Biomodulation Systems (`FB System') for applications in dermatology, wound care, and rare diseases. For more information, go to: www.kloxtechnologies.com
Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets. As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region. Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. At April 30th 2020, Vetoquinol employs 2,403 people. Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO). For more information, go to: www.vetoquinol.com.
About Geller Biopharm, Inc
Geller Biopharm, Inc is an investment banking group focused on licensing advisory services in the healthcare industry. Broker/Dealer services provided by Pickwick Capital Partners, LLC. Member FINRA/ SIPC.